<PAGE>

                                    UNITED STATES
                          SECURITIES AND EXCHANGE COMMISSION
                                Washington, D.C. 20549
                                ----------------------
                                      FORM 10-Q

[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the quarterly period ended December 31, 1997

[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the transition period from ____________ to _____________

Commission File Number O-4136

                              Lifecore Biomedical, Inc.
                -----------------------------------------------
                (Exact name of Registrant as specified in its charter)


                 Minnesota                             41-0948334
     ------------------------------                -------------------
      (State or other jurisdiction of                 (IRS Employer
     incorporation or organization)                Identification No.)

          3515 Lyman Boulevard
             Chaska, Minnesota                             55318
       --------------------------                  -------------------
      (Address of principal executive                   (Zip Code)
                offices)

Registrant's telephone number, including area code:  612-368-4300

Indicate by checkmark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.

                         Yes   X   No
                             -----    -----

The number of shares outstanding of the registrant's Common Stock, $.01 per
value, as of January 15, 1998 was 12,256,928 shares.


<PAGE>


                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

                                      FORM 10-Q

                                        INDEX

                                                                       Page
PART I.   Financial Information

  Item 1. Financial Statements

          Consolidated Condensed Balance Sheets at
          December 31, 1997 and June 30, 1997                             3

          Consolidated Condensed Statements of Operations for Three
          Months and Six Months Ended December 31, 1997 and 1996          4

          Consolidated Condensed Statements of Cash Flows for
          Six Months Ended December 31, 1997 and 1996                     5

          Notes to Consolidated Condensed Financial Statements         6-10

  Item 2. Management's Discussion and Analysis of Results of
          Operations and Financial Condition                          11-13

PART II.  Other Information

  Item 4. Submission of Matters to a Vote of Security Holders            14

  Item 6. Exhibits and Reports on Form 8-K                            14-15

SIGNATURES                                                               16

                                          2
<PAGE>



                            PART 1. FINANCIAL INFORMATION

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES
                        CONSOLIDATED CONDENSED BALANCE SHEETS

                                     (Unaudited)


                                                December 31,         June 30,
                                                    1997              1997
                                                ------------        -----------
ASSETS
Current assets
     Cash and cash equivalents                   $ 2,040,000       $ 1,371,000
     Short-term investments                       11,915,000        16,630,000
     Accounts receivable                           3,830,000         4,792,000
     Inventories                                  10,738,000         8,440,000
     Prepaid expenses                                899,000         1,432,000
                                               -------------      ------------
                                                  29,422,000        32,665,000

Property, plant and equipment
     Land, building and equipment                 20,150,000        19,228,000
     Less accumulated depreciation                (6,226,000)       (5,483,000)
                                                ------------      ------------
                                                  13,924,000        13,745,000

     Construction-in-progress and
      advance deposits                            10,298,000         5,265,000
                                               -------------     -------------
                                                  24,222,000        19,010,000
Other assets
     Intangibles                                   6,049,000         6,306,000
     Long-term investments                                --         3,960,000
     Security deposits                               809,000           786,000
     Inventory                                     2,058,000         1,839,000
     Other                                           727,000           943,000
                                                ------------      ------------
                                                   9,643,000        13,834,000
                                                 -----------      ------------

                                                $ 63,287,000      $ 65,509,000
                                               -------------     -------------
                                               -------------     -------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
     Current maturities of long-term obligations  $  923,000        $  918,000
     Accounts payable                              2,046,000         3,613,000
     Accrued compensation                            873,000           638,000
     Accrued expenses                                606,000           648,000
                                               -------------     -------------
                                                   4,448,000         5,817,000

Long-term obligations                              7,529,000         7,596,000
Shareholders' equity                              51,310,000        52,096,000
                                               -------------     -------------
                                               $  63,287,000     $  65,509,000
                                               -------------     -------------
                                               -------------     -------------

See accompanying notes to consolidated condensed financial statements.


                                          3
<PAGE>

                       LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

                   CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

                                    (Unaudited)

<TABLE>
<CAPTION>

                                 Three months ended December 31,   Six months ended December 31,
                                 ------------------------------    -----------------------------
                                      1997           1996                1997            1996
                                   ----------     ----------        ------------   ------------
<S>                               <C>            <C>                <C>             <C>
Net sales                         $ 6,258,000    $ 4,684,000        $ 11,472,000    $ 8,252,000
Cost of goods sold                  2,838,000      2,511,000           5,365,000      4,609,000
                                   ----------     ----------        ------------   ------------
Gross profit                        3,420,000      2,173,000           6,107,000      3,643,000

Operating expenses
     Research and development       1,140,000        850,000           2,484,000      1,536,000
     Marketing and sales            1,852,000      1,465,000           3,582,000      2,577,000
     General and administrative       849,000        759,000           1,606,000      1,484,000
                                   ----------     ----------        ------------   ------------
                                    3,841,000      3,074,000           7,672,000      5,597,000
                                   ----------     ----------        ------------   ------------

     Loss from operations            (421,000)      (901,000)         (1,565,000)    (1,954,000)

Other income (expense)
     Interest income                  253,000        537,000             548,000      1,092,000
     Interest expense                  (7,000)      (179,000)            (61,000)      (335,000)
                                   ----------     ----------        ------------   ------------
                                      246,000        358,000             487,000        757,000
                                   ----------     ----------        ------------   ------------

Net loss                           $ (175,000)    $ (543,000)       $ (1,078,000)  $ (1,197,000)
                                   ----------     ----------        ------------   ------------
                                   ----------     ----------        ------------   ------------
Net loss per share
     Basic                         $     (.01)    $     (.04)       $       (.09)  $       (.10)
                                   ----------     ----------        ------------   ------------
                                   ----------     ----------        ------------   ------------
     Diluted                       $     (.01)    $     (.04)       $       (.09)  $       (.10)
                                   ----------     ----------        ------------   ------------
                                   ----------     ----------        ------------   ------------
Weighted average
     shares outstanding
     Basic                         12,239,438     12,180,372          12,232,232     12,153,791
                                   ----------     ----------        ------------   ------------
                                   ----------     ----------        ------------   ------------
     Diluted                       12,239,438     12,180,372          12,232,232     12,153,791
                                   ----------     ----------        ------------   ------------
                                   ----------     ----------        ------------   ------------

</TABLE>
 
See accompanying notes to consolidated condensed financial statements


                                          4
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

                   CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

                                     (Unaudited)

<TABLE>
<CAPTION>

                                                                  Six months ended
                                                                    December 31,
                                                          ---------------------------------
                                                              1997                1996
                                                          ------------        ------------
<S>                                                       <C>                 <C>
Net cash used in operating activities                     $ (2,457,000)       $ (3,286,000)

Cash flows from investing activities:
     Purchases of property, plant and equipment             (5,956,000)           (836,000)
     Purchases of investments                               (2,984,000)         (7,756,000)
     Maturities of investments                              11,652,000           9,934,000
     Purchases of intangibles                                  (24,000)             (5,000)
     Other                                                     207,000              76,000
                                                           -----------         -----------
Net cash provided from investing activities                  2,895,000           1,413,000

Cash flows from financing activities:
     Payment of deposit to bond trustee                        (40,000)            (38,000)
     Payments of long-term obligations                         (21,000)            (86,000)
     Proceeds from stock issuance                              292,000             173,000
                                                           -----------         -----------
Net cash provided from financing activities                    231,000              49,000
                                                           -----------         -----------

Net increase (decrease) in cash and cash equivalents           669,000          (1,824,000)
Cash and cash equivalents at beginning of period             1,371,000           3,264,000
                                                           -----------         -----------

Cash and cash equivalents at end of period                 $ 2,040,000         $ 1,440,000
                                                           -----------         -----------
                                                           -----------         -----------
Supplemental disclosure of cash flow information:
     Cash paid during the period:
       Interest                                             $  353,000          $  356,000

</TABLE>

See accompanying notes to consolidated condensed financial statements.


                                          5
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

                 NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS

                                  December 31, 1997

NOTE A - FINANCIAL INFORMATION

Lifecore Biomedical, Inc. ("the Company"), develops, manufactures, and markets
surgically implantable materials and devices through two divisions, the
Hyaluronate Division and the Oral Restorative Division.  The Hyaluronate
Division's manufacturing facility is located in Chaska, Minnesota and markets
products through OEM and contract manufacturing alliances in the fields of
ophthalmology, veterinary and wound care management.  The Oral Restorative
Division markets products through direct sales in the United States and Italy
and through distributors in other foreign countries.

The accompanying unaudited consolidated condensed financial statements have been
prepared in accordance with Regulation S-X pursuant to the rules and regulations
of the Securities and Exchange Commission.  Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to such rules and regulations, although management believes that the
disclosures are adequate to make the information presented not misleading.

In the opinion of management, the unaudited consolidated condensed financial
statements contain all adjustments (consisting of only normal recurring
adjustments) necessary to present fairly the financial position as of December
31, 1997, and the results of operations and cash flows for the three-and
six-month periods ended December 31, 1997 and 1996.  The results of operations
for the six months ended December 31, 1997, are not necessarily indicative of
the results for the full year or of the results for any future periods.

In preparation of the Company's consolidated financial statements, management is
required to make estimates and assumptions that affect reported amounts of
assets and liabilities and related revenues and expenses.  Actual results could
differ from the estimates used by management.


                                          6
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

NOTE B - INVESTMENTS

The Company has invested excess cash in commercial paper, government agencies
and medium term corporate notes.  These investments are classified as
held-to-maturity given the Company's intent and ability to hold the securities
to maturity and are carried at amortized cost.  Investments that have maturities
of less than one year have been classified as short-term investments.  At
December 31, 1997, and June 30, 1997, amortized cost approximates fair value of
held-to-maturity investments which consist of the following:


                                                 December 31,        June 30,
                                                     1997             1997
                                               --------------   -------------
                                                         (Unaudited)

Short-term investments:
     Medium term corporate notes               $  11,915,000    $  12,800,000
     Commercial paper                                    ---        2,627,000
     U.S. Government Agencies                            ---        1,203,000
                                               -------------    -------------
                                               $  11,915,000    $  16,630,000

Long-term investments:
     Medium term corporate notes                         ---        3,960,000
                                               -------------    -------------
                                                         ---        3,960,000
                                               -------------    -------------
                                               $  11,915,000    $  20,590,000
                                               -------------    -------------
                                               -------------    -------------

NOTE C - INVENTORIES

Inventories are stated at the lower of cost (first-in, first-out method) or
market.  Inventory not expected to be consumed within one year is classified as
a long-term asset.  Inventories consist of the following:


                                                December 31,       June 30,
                                                    1997            1997
                                               -------------    -------------
                                                         (Unaudited)

     Raw materials                              $  3,455,000     $  2,819,000
     Work in progress                                149,000          205,000
     Finished goods                                9,192,000        7,255,000
                                               -------------    -------------
                                               $  12,796,000     $ 10,279,000
                                               -------------     ------------
                                               -------------     ------------


                                          7
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

NOTE D - AGREEMENTS

In 1994, Lifecore and Ethicon, Inc. ("Ethicon"), a subsidiary of Johnson &
Johnson, Inc., entered into a Conveyance, License, Development and Supply
Agreement (the "Ethicon Agreement"). Under the terms of the Ethicon Agreement,
Ethicon transferred to Lifecore its ownership in certain technology related to
research and development previously conducted on the Company's sodium
hyaluronate material.  The technology transferred to Lifecore includes written
technical documents related to Ethicon's research and development of a product
to inhibit the formation of surgical adhesions.  These documents include product
specifications, methods and techniques, technology, know-how and certain patent
applications which have subsequently become issued patents.  Lifecore has
assumed responsibility for continuing the anti-adhesion development project,
including conducting human clinical trials on INTERGEL-TM- Adhesion Prevention
Solution (formerly known as LUBRICOAT Gel), a second generation
hyaluronate-based product.  Lifecore has granted Ethicon exclusive worldwide
marketing rights through 2008 to the products developed by Lifecore within
defined fields of use.

The Company has made and continues to make a significant investment in the
development and testing of INTERGEL-TM- Adhesion Prevention Solution, a product
designed to reduce the incidence of postsurgical adhesions.  The product is
currently undergoing human clinical trials to develop the data necessary to
apply to the United States Food and Drug Administration ("FDA") for clearance to
market the product for commercial application.  However, even if the product is
successfully developed and the Company receives clearance from the FDA, there
can be no assurance that it will receive market acceptance.  Failure to achieve
significant sales of the product could have a material adverse effect on future
prospects for the Company's operations.


NOTE E - COMMITMENTS

The Company is in the process of expanding its manufacturing and distribution
capabilities at its Chaska, Minnesota location.  This expansion includes
building and equipment expenditures for warehouse and distribution capabilities
and to expand aseptic-packaging facilities for finished products.
Construction-in-progress and advance deposits relating to the expansion of
approximately $10,298,000 were incurred through December 31, 1997.  The Company
has signed contracts with an architect, a process engineering firm and a
construction company for the expansion project.  The contracts provide for the
expansion to be completed in phases.  The contracts may be terminated at any
time at minimal cost to the Company.  At December 31, 1997 and June 30, 1997,
firm purchase commitments of approximately $969,000 and $2,161,000,
respectively, have been recorded in accounts payable.


                                          8
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

NOTE F - CAPITALIZED INTEREST

During the six months ended December 31, 1997, $345,000 of interest has been
capitalized in conjunction with the facility expansion project.


NOTE G - LINE OF CREDIT

On January 15, 1998, the Company entered into a $5,000,000 Credit Agreement and
Revolving Credit Note with a bank.  The agreement allows for advances against
eligible securities and eligible accounts receivable, subject to a borrowing
base certificate.  Interest is accrued at either the prime rate or the
Eurodollar Rate plus a basis point adjustment as defined in the Credit
Agreement.   The Revolving Credit Note matures on October 31, 1998.


NOTE H - NET LOSS PER SHARE

On December 31, 1997, the Company adopted Statement of Financial Accounting
Standards No. 128 - "Earnings per Share".   As required by Statement No. 128,
all current and prior year loss per share data have been restated to conform to
the provisions of Statement No. 128.

The Company's basic net loss per share amounts have been computed by dividing
net loss by the weighted average number of outstanding common shares.  For the
three and six months ended December 31, 1997 and 1996, the Company reported net
losses and as such,  no common share equivalents were included in the
computation of diluted net loss per share.  However, if the Company would have
reported net earnings in the three and six months ended December 31, 1997 and
1996, the common share equivalents that would have been included in the
computation of diluted net earnings per share are set forth below.


                                          9
<PAGE>


                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

NOTE H - NET LOSS PER SHARE (continued)

                                 Three Months Ended         Six Months Ended
                                    December 31,               December 31,
                                   1997      1996         1997        1996
                                 --------  -------     --------     -------
 Common Stock Equivalents        473,425   288,128     321,410      299,150


Options to purchase 233,500 and 46,500 shares of common stock with a weighted
average exercise price of $20.24 and $18.72 were outstanding at December 31,
1997 and 1996, respectively, but were excluded from the computation of common
share equivalents because their exercise prices were greater than the average
market price of the common shares.


NOTE I - RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In June 1997, the Financial Accounting Standards Board ("FASB") issued Statement
No. 130 "Reporting Comprehensive Income" and Statement No. 131 "Disclosures
about Segments of an Enterprise and Related Information" which are effective for
fiscal year 1999.  Statement No. 130 will require the Company to display an
amount representing comprehensive income, as defined by the statement, as part
of the Company's basic financial statements.  Comprehensive income will include
items such as unrealized gains or losses on certain investment securities and
foreign currency items.  Statement No. 131 will require the Company to disclose
financial and other information about its business segments, their products and
services, geographic areas, major customers, revenues, profits, assets and other
information.

The adoption of these statements is not expected to have a material effect on
the consolidated financial statements of the Company.


                                          10
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

            ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF
                         OPERATIONS AND FINANCIAL CONDITION

RESULTS OF OPERATIONS

THREE AND SIX MONTHS ENDED DECEMBER 31, 1997 COMPARED TO THREE AND SIX MONTHS
ENDED DECEMBER 31, 1996

Net sales for the three-and six-month periods ended December 31, 1997 increased
$1,574,000 and $3,220,000, respectively, an increase of 34% and 39%,
respectively, compared with the same periods of last fiscal year.  Hyaluronate
product sales increased 27% and 40% for the three-month and six-month periods
ended December 31, 1997 as compared to the periods of last fiscal year primarily
from increased sales to ophthalmic and veterinary customers.  The increased
sales to ophthalmic and veterinary customers were partially offset by a decrease
in revenues from development projects compared to the same quarter of last
fiscal year.  Oral restorative product sales for the three-month and six-month
periods ended December 31, 1997 increased 38% for both periods compared to the
same periods of last fiscal year.  This increase is a result of the introduction
of new tissue regeneration products, increased market awareness in the domestic
market and expanded distribution networks in international markets.

Cost of goods sold as a percentage of net sales decreased to 45% and 47%,
respectively, for the three-month and six-month periods ended December 31, 1997
from 54% and 56% for the same periods last fiscal year.  The decrease resulted
from spreading fixed expenses over increased product sales and from production
efficiencies gained in hyaluronate and aseptic production.

Research and development expenses increased $290,000, or 34%, for the current
quarter as compared to the same quarter of last fiscal year and $948,000, or
62%, for the six months ended December 31, 1997 as compared with the same period
of last fiscal year.  The increase is principally attributed to costs associated
with human clinical trials for INTERGEL-TM- Adhesion Prevention Solution and to
a lesser extent, higher personnel costs due to increased headcount.

Marketing and sales expenses increased $387,000, or 26%, for the current quarter
as compared to the same quarter of last fiscal year and $1,005,000, or 39%, for
the six months ended December 31, 1997.  The increase is principally attributed
to the expansion of the oral restorative domestic sales force and to a lesser
extent, increased marketing efforts in conjunction with the new tissue
regeneration products.


                                          11
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

             ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF
                      OPERATIONS AND FINANCIAL CONDITION (CONT.)

General and administrative expenses increased $90,000, or 12%, for the current
quarter as compared to the same quarter of last fiscal year and $122,000, or 8%,
for the six months ended December 31, 1997.  The increase was primarily caused
by amortization of goodwill associated with the TefGen product line which was
purchased in May 1997.

Other income (expense) for the three and six months ended December 31, 1997
decreased $112,000 and $270,000, respectively, compared with the same periods of
last fiscal year.  The decrease in interest income is primarily a result of the
utilization of cash and investments to fund current operations and the facility
expansion.  The decrease in interest expense is a result of the capitalization
of interest expense associated with the facility expansion.

On December 31, 1997, the Company adopted Statement of Financial Accounting
Standards No. 128 - "Earnings per Share".  As required by Statement No. 128, all
current and prior year loss per share data have been restated to conform to the
provisions of Statement No. 128.  For the three-and six-month periods ended
December 31, 1997 and 1996, the application of Statement No. 128 had no dilutive
effect due to the reporting of net losses.


LIQUIDITY AND CAPITAL RESOURCES

The Lifecore Annual Report on Form 10-K for the year ended June 30, 1997
contains a detailed discussion of the Company's liquidity and capital resources.
In conjunction with this Quarterly Report on Form 10-Q, investors should read
the 1997 Form 10-K.

The Company has had significant operating cash flow deficits for the last 
three fiscal years.  As the Hyaluronate Division's production increases, its 
related production efficiencies increase.  However, research and development 
costs for INTERGEL-TM- Adhesion Prevention Solution, marketing and sales 
expenses for the oral restorative products, and personnel costs have 
increased.  The Company is in the process of expanding its manufacturing and 
distribution capabilities at its Chaska, Minnesota location.  This facility 
expansion includes building and equipment expenditures for warehouse and 
distribution capabilities and to scale-up aseptic-packaging facilities for 
finished products. Construction-in-progress and advance deposits related to 
the facility expansion of approximately $10,298,000 were incurred through 
December 31, 1997.  The Company has signed contracts with an architect, a 
process engineering firm and a construction company for the


                                          12
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

             ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF
                      OPERATIONS AND FINANCIAL CONDITION (CONT.)

expansion project.  The contracts provide for the expansion to be completed in
phases.  The contracts may be terminated at any time at minimal cost to the
Company.  Lifecore anticipates that approximately $8-10 million will be expended
in the remainder of fiscal year 1998 to complete the expansion project.  Funding
will result from the redemption of investments, which at December 31, 1997
aggregate approximately $12 million.

On January 15, 1998, the Company entered into a $5,000,000 Credit Agreement and
Revolving Credit Note with a bank.  The agreement allows for advances against
eligible securities and eligible accounts receivable, subject to a borrowing
base certificate.  Interest is accrued at either the prime rate or the
Eurodollar Rate plus a basis point adjustment as defined in the Credit
Agreement.   The Revolving Credit Note matures on October 31, 1998.

Certain statements in this Form 10-Q are forward-looking statements as defined
in the private Securities Litigation Reform Act of 1995.  Such statements imply
continued financial improvement.  Because of numerous risks and uncertainties in
Lifecore's business activity, actual results may differ materially from those
implied.  Investors are referred to more detailed discussions of those risks
presented in the Company's Annual Report on Form 10-K.

                                          13
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

                                       PART II

                                  OTHER INFORMATION


Item 4.   Submission of Matters to a Vote of Security Holders

          On November 13, 1997, the Company held its Annual Meeting of
          Shareholders.  At the meeting, the shareholders elected as directors
          Orwin L. Carter (with 9,392,539 affirmative votes and 35,150 negative
          votes) and Donald W. Larson (with 9,322,691 affirmative votes, and
          104,998 negative votes).

          The shareholders also ratified the appointment of Grant Thornton LLP
          as the Company's independent public accountants for fiscal year
          1998 with 9,390,042 affirmative votes, 24,743 negative votes and
          12,904 votes abstained).


Item 6.   Exhibits and Reports on Form 8-K

     a.   Exhibits and Exhibit Index

Exhibit             Description
Number              -----------
------

 10.1     Employment Agreement dated June 1, 1991 with James W. Bracke
          (incorporated by reference to Exhibit 10.11 to 1991 S-2 Registration
          Statement [File No. 33-41291]), as amended by letter agreement dated
          August 15, 1995 (incorporated by reference to Exhibit 10.6 to Form
          10-K for the year ended June 30, 1995), as amended by letter agreement
          dated November 14, 1996, filed herewith

 10.2     Credit Agreement dated January 15, 1998 between the Company and First
          Bank National Association, filed herewith

 10.3     Revolving Credit Note dated January 15, 1998 between the
          Company and First Bank National Association, filed herewith

 10.4     Security Agreement dated January 15, 1998 by the Company in favor of
          First Bank National Association, filed herewith


                                          14
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES

                                       PART II

                            OTHER INFORMATION (CONTINUED)


 10.5     Custodial Pledge and Security Agreement dated January 15, 1998 by and
          between the Company, Norwest Investment Services, Inc., and First Bank
          National Association, filed herewith

 27       Financial Data Schedule


  b.      Reports on Form 8-K

          On December 15, 1997, the Company filed a report on Form 8-K to
          report the completion of the initial analysis of the data obtained 
          from its pivotal clinical trial evaluating the use of Intergel 
          Adhesion Prevention Solution in female abdominal surgery patients.


                                          15
<PAGE>

                      LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES


                                      SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                   LIFECORE BIOMEDICAL, INC.



Dated:  January 28, 1998      /s/ James W. Bracke
                              -------------------------
                              James W. Bracke
                              President & Chief Executive Officer


Dated:  January 28, 1998      /s/ Dennis J. Allingham
                              -------------------------
                              Dennis J. Allingham
                              Executive Vice President & Chief Financial Officer
                              Principal Financial Officer)


                                          16